Novel Compounds Acting Through Receptors and Enzyme Mediators
This article will introduce novel steroids that have an optimal profile for the prevention of postmenopausal osteoporosis. These agents have a duality of function: they can activate the estrogen receptor (ER) but they also regulate the amount of ligand available for the ER via enzyme inhibition in a tissue-specific manner. These agents have the same clinical profile as selective estrogen receptor modulators (SERMS) but a different mode of action. This article will develop these mechanistic concepts.
KeywordsEstrogen Osteoporosis Testosterone Tamoxifen Progesterone
Unable to display preview. Download preview PDF.
- 2.Kuiper GGJM, Nilson S, Gustaffsson J-A. Characteristics and function of the novel estrogen receptor β. In: O’Malley BW, editor. Hormones and signaling. New York: Academic Press, 1998: 90–112.Google Scholar
- 3.Truss M, Beato, M. Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocrine Rev 1993; 14:459–79.Google Scholar
- 11.Jin Y, Penning, TM. Steroid 5α-reductases and 3a-hydroxysteroid dehydrogenases: Keyenzymes in androgen metabolism. In: Seckl, JR, Walker, BR editors. Disorders of steroid metabolism. Holly, JMP, series editor. Best Practice & Research: Clinical Endocrinology and Metabolism. London: Bailliare Tindall 2000; 15:79–94.Google Scholar
- 16.Penning TM, Burczynski ME, Jez JM, et al. Human 3a-hydroxysteroid dehydrogenase isoforms (AKR1C1-AK1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000; 351:67–77.PubMedCrossRefGoogle Scholar
- 17.Miettinen MM, Mustonen MV, Poutanen MH, Isomaa VV, Vihko, RK. Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic celland tissue-specific expression. Biochem J 1966; 314:839–45.Google Scholar
- 21.Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anti-cancer Res 1997; 17:135–40.Google Scholar
- 22.Chetrite G, Kloosterboer HJ, Phillipe J-C, Pasqualini, JR. Effects of Org OD14 (Livial) and its metabolites on 17β-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells. Anti-cancer Res 1999; 19:261–68.Google Scholar
- 23.Kloosterboer HJ, de Gooyer ME. Tibolone inhibits sulfatase activity in breast but not in the bone. Proceedings 9th International Menopause Symposium 1999 Oct 17–21; Yokohama, Japan P349.Google Scholar